drugset / Trial / NCT00034944

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)

NCT00034944

Phase 3 Completed 495 enrolled Merck Sharp & Dohme LLC
Double-blindTreatment

Summary

A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression.

Timeline

Start
2002-01-24
Primary completion
2003-12-17
Completion
2003-12-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Aprepitant Other / unclassified 80 mg
Subject Aprepitant Other / unclassified 160 mg